Decrease in SLEDAI score/clinical response in 83%/67% of patients at day 62 (significant decrease already after 2nd cycle), improvement / resolution in arthritis, myositis, rash, alopecia; no severe disease flare; PGA ↓; frequency of BILAG severity categories A and B ↓; complement C3 ↑ (during cycles); anti-dsDNA-Abs =. This evidence concerns the gene C3 and myositis disease.